Paris (France), April 11, 2018 – the G5 Health Association announced the appointment of Yves L’Epine as Chairman of the association.
As announced on March 29 last, Marc de Garidel, Chairman of the G5 Health Association since 2011, wished to cease all responsibility within the association.
The members of the G5 Health Association appointed Yves L’Epine, CEO of the Guerbet Group, to succeed him as Chairman of the association.
« I would like to offer Marc my sincere congratulations for his work during his seven years as Chairman of the G5 Health Association. The quality of the work led by the think tank has been a driving force for proposals, which have been heard and recognized », said Yves L’Epine.
« I intend to continue and strengthen the collective work of the association. The G5 Health Association includes Chairmen and CEOs of Groups that embody France’s excellence in terms of healthcare companies, serving innovation and patients. Through their decisions, these leaders drive their research programs, clinical studies investments in production and as a result create jobs, in France and abroad. Thus, they are highly committed to ensuring that our country’s regulatory, social and economic ecosystem becomes more favorable in the future, to become more successful, particularly abroad. Much like public authorities, they are convinced that healthcare companies are strategic for our country, in the same way as aerospace, national defence, automotive and agri-food companies. »
To strengthen the G5 Health Association in a context of far-reaching transformation in the healthcare industry, Didier Véron, Senior Vice-President, Public Affairs & Corporate Communications of the Ipsen Group, becomes “Délégué Général” of the association
About Yves L’Epine
Doctor of medicine (René Descartes University), Yves L’Epine practiced cardiology and interventional radiology as part of the Assistance Publique des Hôpitaux de Paris (The City of Paris public hospitals board) up to 1989. He also holds an MBA degree from INSEAD (European Institute of Business Administration- 1990).
Yves l’Epine pursued an international career in the pharmaceutical industry, first with the Sandoz Group, then Novartis, across several countries and in various positions of increasing responsibility, before becoming CEO of the French subsidiary of the Takeda Group, then European Vice-President of Abbott.
Since 2011, Yves L’Epine has held the position of Managing Director of the Guerbet Group. Guerbet, one of the global leaders in medical imaging, offers a large range of pharmaceutical products and medical devices, as well as digital solutions. The product range is divided into two business activities: diagnostic and interventional imaging. These two business activities have been strengthened by the recent acquisitions of foreign companies. With a workforce of 2,800 employees, Guerbet is present on every continent and achieves 85% of its revenue outside France. However, most of the Group’s R&D and production activities are in France.
About the G5 Health Association (hhtp://www.g5.asso.fr)
The G5 Health Association, which is the voice of the French healthcare industry, is a think-tank that includes the leaders of the major French health and life science companies (bioMérieux, Guerbet, Ipsen, Laboratoires Théa, LFB, Pierre Fabre, Sanofi, Servier). These companies chose France as a platform for their international development and have made R&D activities their priority. The members of the G5 Health Association share 5 ambitions: gaining recognition of the crucial contribution of the life science industries as a key player in French public health, contributing to the recovery of France’s competitiveness, a strong commitment to French biomedical research excellence, development of patients’ access to health solutions and supporting the biotechnology and new technologies sector.
Dider Véron – Tel: +33 (0) 1 58 33 51 16
Revenir à la liste des articles